SAB BIOTHERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
SAB BIOTHERAPEUTICS, INC. (SABS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $775.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was -$143.00.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $775.14K, a 68.00% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $191.00.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $2.42M, a 557.44% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $368.43K, a 62.93% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $993.81K, a 1426.87% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $65.09K, a 87.12% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$143.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $775.00K 10-Q · filed 2026-08-06 | $775.00K derived: sum of 3 quarters · filed 2026-08-06 | $775.19K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $775.14K 10-Q · filed 2026-05-12 | $775.14K derived: sum of 2 quarters · filed 2026-05-12 | $775.33K derived: sum of 3 quarters · filed 2026-05-12 | $775.14K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $191.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $2.42M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $191.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $2.42M 10-Q · filed 2025-11-14 | $2.42M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$191.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.42M 10-Q · filed 2026-08-06 | $2.42M 10-Q · filed 2025-08-07 | $2.42M derived: sum of 3 quarters · filed 2026-08-06 | $2.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-12 | $2.42M derived: sum of 2 quarters · filed 2026-05-12 | $2.42M derived: sum of 3 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $368.43K 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $368.43K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $368.43K 10-Q · filed 2025-08-07 | ||||
| 2023-12-31 | $993.81K 10-K · filed 2025-03-31 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $65.09K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $65.09K 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | $244.50K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $505.19K 10-K/A · filed 2023-04-28 | |||
| 2021-09-30 | $260.68K 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $1.77M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |